53797-35-6
Chemical Structure
Ribostamycin sulfate
Synonym(s): Vistamycin sulfate
- CAS No.: 53797-35-6
- Formula:C17H36N4O14S
- Molecular Weight:552.55
IUPAC Name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2-(((2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-3-hydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4-diol sulfate
InChIKey: RTCDDYYZMGGHOE-YMSVYGIHSA-N
SMILES: O=S(O)(O)=O.O[C@@H]([C@H](O)[C@@H](CN)O1)[C@@H](N)[C@@]1([H])O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@]2([H])O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O
Biological Activity:
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ribostamycin sulfate | 99.55% | Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant KD of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Horibe T, et al. Ribostamycin Inhibits the Chaperone Activity of Protein Disulfide Isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-972.
- [2]. Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020;11:1718. Published 2020 Jul 29. [Content Brief]
- [3]. Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17(3):203-208. [Content Brief]
- [4]. Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018;164:185-191. [Content Brief]
Keywords
